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Summary The relative efficacies of cytotoxic chemotherapy regimens in the treatment of advanced breast
cancer are generally assessed by comparing response rates in randomised trials. Treatment attempts to
prolong survival but trials rarely demonstrate a statistically significant survival advantage: it has been argued
that chemotherapy does not prolong survival.
The correlation between response rates and survival has been examined by reviewing 79 comparisons
between arms with unequal response rates in 50 published trials of chemotherapy in advanced breast cancer.
In 73% of comparisons the group with the higher response rate also demonstrated the longer median survival
(P<0.001). Weighted linear regression showed a statistically significant relationship between relative response
rates and survival (P<0.001). The number of patients in a comparison did not influence this relationship.
For the woman with metastatic breast cancer, systemic
therapy with cytotoxic drugs is generally considered to be
the only alternative to pure symptom relief after the failure
of endocrine therapy. Whilst the chances of a long term cure
for an individual are accepted to be remote, cytotoxics are
used in the hope of both palliating symptoms and improving
survival. The benefits of chemotherapeutic regimens must be
weighed against their numerous and severe side effects.
The relative merits of cytotoxic regimens in controlling the
disease are usually measured using the objective response
rate. Such trials rarely demonstrate a statistically significant
survival advantage in favour of the arm with the higher
response rate. This could be because increased objective
tumour response does not translate into a survival benefit.
Another possible explanation is that individual trials lack
sufficient statistical power to detect survival differences
because such differences are small. In order to determine
survival benefit we have therefore examined the correlation
between response rates and survival by reviewing randomised
trials in advanced breast cancer.
The relationship between response rate and survival was
studied by comparing arms from the same trial. Arms from
different trials were not compared directly because differing
patient characteristics between trials would confound such
comparisons that are normally compensated for by ran-
domisation within a trial. The hypothesis tested was that if
cytotoxic chemotherapy improved survival in advanced
breast cancer there would be a tendency for the arm
demonstrating the higher response rate to also demonstrate a
longer median survival. The relationship between the odds
ratio summarising the response rates in the two arms and the
estimated hazard ratio calculated from the ratio of the
median survivals was investigated.
Materials and methods
This study uses only published data and papers; these will
have been subject to peer review. Such an approach has been
advocated by Chalmers et al (1986) to ensure data quality in
meta-analyses.
Trials of chemotherapy in advanced breast cancer report-
ing survival data have been identified by reference to a
comprehensive review article, (Macauley & Smith, 1986).
Fifty of these trials had unequal response rates in two or
more arms and could therefore be used to address the
hypothesis tested in this study. Median trial size was 94
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patients and ranged from 29 to 448 patients. There were a
total of 6,056 patients in these trials. The inclusion of trials
in the review article was not based on a desire to examine
the relationship investigated in this study, hence selection
bias, which may be a confounding factor in studies such as
this (Chalmers et al., 1986), has been reduced. For each trial
the number of patients, the response rate and the median
survival in each arm were recorded. A list of the trials
considered may be obtained from the authors.
The data given for four trials were incomplete. In two
trials, with a total of 93 patients, the exact median survival
was not known in the arm with the higher response rate. The
median survival was only known to exceed a given value
which was longer than the median survival in the arm with
the lower response rate. In both these cases this minimum
value was used as the median survival, thus the survival
benefit was underestimated in these two instances. In the
other two trials, each of which had two arms, the numbers
of patients in individual arms was not given, only the overall
number of patients in the trial was supplied. In these cases
equal numbers of patients were assumed to have been
randomised to each arm. These two trials had a total of 173
patients.
Trials with more than two arms contributed more than
one comparison to the study, e.g., trials with three arms
contributed three comparisons corresponding to the three
possible pairs formed from the arms. A comparison between
two arms of a trial was considered to be a chemotherapy
comparison if:
(1) the only difference between the regimens given to the
two arms was one or more chemotherapeutic agents. Predni-
sone was not considered to be a chemotherapeutic agent.
However, if two arms differed by one or more chemothera-
peutic agents and prednisone the comparison was included in
the study (this applied to 8 comparisons).
(2) if two arms differed only in the dose or schedule of
one or more chemotherapeutic agents.
Data was collected in the following form:
Number of
Arm responders
A RA
B RB
Number of
nonresponders
NA
NB
Each arm of the trial was individually coded and entered
together with the response rate and median survival into a
database created specifically for this purpose on a Prime
2655 computer. Statistical analysis was performed using
BMDP Statistical Software, Programme version April 1985.
Response
An estimate of the log odds ratio was used to summarise the
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relative response rates of each comparison. The rationale for
the choice of this statistic is given in Appendix I. The
convention was adopted of expressing the odds ratio as the
odds of the group with the highest response rate divided by
the odds of the group with the lower response rate. The
natural logarithm of the odds ratio (LOR) was used in this
study, i.e., they were taken to the base e=2.718. The LOR is
zero when the response rates are equal, because the OR was
expressed as the odds of the arm with the higher response
rate divided by the odds of the arm with the lower response
rate, LOR is always greater than zero.
The formula used to calculate the odds ratio was:
(RA+0.5)(NB+0.5) Odds ratiO= (NA+0.5)(RB+0.5)
Survival
The median survival is commonly used to summarise sur-
vival. The ratio of median survivals was chosen as the most
appropriate method of summarising the relative survival in
two arms in this study. This measure has the advantage of
being an estimate of the hazard ratio if survival follows an
exponential (constant hazard) model. A common assumption
made when fitting such models to survival data is that the
log hazard ratio is normally distributed, this makes the log
hazard ratio a suitable dependent variable for linear regres-
sion. The hazard ratio was estimated by dividing the median
survival of the group with the higher response rate by the
median survival of the group with a lower response rate.
Median survival arm A
Estimated Hazard Ratio (EHR). Median survival arm B
The natural logarithm of the estimated hazard ratio
(LEHR) was employed. When the median survivals are
identical LEHR is 0. LEHR is positive when the group with
the improved response rate also has a longer median survival
and negative when this group has a shorter survival. In one
trial the median survivals were not given but the proportions
surviving at a given time were supplied, the hazard ratio was
estimated from these assuming an exponential survival model
was applicable.
difference in response rates there can be no difference in
survival benefiting the group with the higher response rate.
The regression equation
LEHR=(A +B [no. of pts]) x LOR
+(C+D [no. of pts]) x LOR2
was fitted to the data in a stepwise fashion, where A, B, C
and D are the regression coefficients.
Coefficients A and C represent the relationship between
the LEHR and LOR, if they are zero this would indicate
there is no evidence that a relationship exists.
Coefficients B and D allow for modification of the
relationship between LEHR and LOR according to the
number of patients in a comparison, these coefficients were
used to assess bias, if they were zero it would indicate that
the estimated relationship is independent of comparison size.
This method was extended to consider terms in LOR
cubed.
Results
There were a total of 79 comparisons between arms from the
50 trials reviewed.
The Spearman rank corrrelation between LOR and the total
number of patients in a comparison was -0.42, (P<0.001),
hence a relationship exists between the relative response rates
and the number of patients in a comparison.
The correlation between LEHR and the number of
patients in a comparison was -0.10, (ns), suggesting that
there is no relationship between the number of patients and
survival difference.
Figure 1 shows a plot of LEHR versus LOR. If there were
no association between survival (LEHR) and response
(LOR) one would expect 50% of comparisons to show a
favourable LEHR associated with the group with the highest
response rate. In 73% of comparisons the arm with the
higher response rate also demonstrated a longer median
survival.
Further examination of this relationship was performed
using weighted linear regression. The regression equation
which gave the best fit to the data was found to be of the
form
Methodology
The correlations between LEHR and the number of patients
in a comparison and LOR and the number of patients in a
comparison, were both examined using Spearman's rank
correlation.
The relationship between LOR and LEHR was investi-
gated using weighted linear regression. The inverse of the
variance of the log odds ratio was used as the weighting
factor, thus greater weight was given to those comparisons in
which the log odds ratio was known with greater precision,
i.e., the comparisons with the most patients.
This weighting factor was therefore:
1
LEHR=A x LOR+Cx LOR2.
LEHR
1.0
0.5
1
Variance I + 1 + 1
RA+0.5 NA+0.5 RB+O.5 NB+0.5
A further weighting factor was also included to compensate
for the fact that the comparisons are not independent in
trials with more than two arms. In a three arm trial, for
example, there are two independent comparisons. In this
instance each comparison was weighted by a factor of 2/3,
the weight being the number of independent comparisons
divided by the total number of comparisons. Similarly in a
four arm trial a weighting factor of 3/6 was used.
The regression relationship was constrained so that LEHR
was zero when the LOR was zero, i.e., if there is no
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Figure 1 A plot of the log estimated hazard ratio (LEHR)
against the log odds ratio (LOR). In all of those comparisons
with an LEHR greater than zero the longer median survival is in
the group with the higher response rate. Comparisons with an
LEHR less than zero showed a shorter median survival in the
group with higher response.
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Estimates of the coefficients A and C are shown in the
following table. This equation was not improved by the
inclusion of either term involving the number of patients in a
comparison, or by a cubic term in LOR.
A
C
Coefficient
0.380
-0.116
s.e. t value
0.07 5.14
0.05 -2.28
P value
P<0.001
P=0.02
This corresponds to the equation:
LEHR=0.380xLOR-0.l16xLOR2.
The correlation coefficient R between LEHR and LOR
was 0.61, thus 37% of the variation seen in survival can be
explained by variation in response rates. Appendix II con-
tains statistical details of the fitting of the regression equa-
tion. Exclusion of the eight comparisons which included
prednisone in one arm yielded similar results (A=0.373 and
C= -0.113).
Table I shows hypothetical examples derived from the
above equation. The expected improvement in median sur-
vival corresponding to differences in response rates between
two arms of a randomised trial are shown. It has been
assumed the arm with the lower response rate has a response
rate of 20% and a mean survival of 18 months.
Discussion
The strongest evidence for an effect of chemotherapy upon
the survival of women with advanced breast cancer would
come from a prospective randomised trial comparing an
effective chemotherapeutic regimen against an arm receiving
purely symptomatic treatment, i.e., a trial of a regimen with
a high response rate versus an arm with a zero response rate.
At present such a study would be unlikely to receive ethical
committee approval. Indirect methods of addressing this
question include the use of non-randomised series and the
use of historical controls.
Powles et al. (1980) examined the notes of 78 patients who
received no chemotherapy and 80 patients who had received
one of three chemotherapeutic regimens. There was no
survival difference between the two groups from the time of
first detection of metastatic disease, in fact patients who had
survived one year since the first detection of their metastasis
appeared to do worse with chemotherapy. Survival was
increased by a factor of four in the responders to cytotoxic
agents.
This study generated a vitriolic correspondence. However
its findings were to be duplicated by a similar retrospective
review of 483 patients by Patel et al. (1986) who considered
patients treated between 1942 and 1975. It was found that
despite a changing trend in therapy away from radiation and
Table I Hypothetical examples derived from the
fitted regression equation. The expected improve-
ment in median survival corresponding to differ-
ences in response rates between two arms of a
randomised trial are shown. It has been assumed
the arm with the lower response rate has a res-
ponse rate of 20% and a median survival of 18
months.
Response rate in arm
with higher response rate
(%)
Baseline 20
30
40
50
60
70
Estimated
median survival
(months)
18.0
21.4
23.4
24.4
24.5
23.6
Table II Predicted values of LEHR for given
values of LOR over the range zero to 2.5.
Predicted values for models without a quadratic
term and with a quadratic term are shown
Predicted LEHR
Model Model
LOR A*LOR A*LOR+C*LOR2
0.0 0.0 0.0
0.5 0.12 0.16
1.0 0.23 0.26
1.5 0.35 0.31
2.0 0.47 0.30
2.5 0.59 0.23
additive hormones towards chemotherapy and ablative hor-
mones there was no increase in survival time from first
diagnosis, or metastatic survival time, (from appearance of
first metastasis). Whilst a similar conclusion was drawn by
Paterson et al. (1982), closer inspection of their data suggests
that an improvement in survival achieved by combination
chemotherapy when compared to historical controls may
have been missed due to a type II error.
Postulating that 'some of the enthusiasm for combination
chemothrapy regimes may be due to the premature reporting
of protocol results or emphasis on response rates rather than
survival', Ross et al. (1985) reviewed patients treated over
three decades. During the 1950s most patients had received
endocrine therapy with the emphasis shifting slightly towards
the hesistant use of single agent chemotherapy in the 1960s,
followed by a large swing during the 1970s, when the
majority received combination cytotoxics. The retrospective
analysis of survival even when corrected for confounding
variables showed an improvement in the 1970s which was
attributed to the change in treatment.
Attention has recently turned to the outcome of treatment
by comparison of survival times of patients in randomised
trials of various treatments (Brambilla et al., 1976; Rubens et
al., 1977; Priestman et al., 1978). A common feature in these
trials is the improved survival of the responders when
compared with the non-responders to the treatment being
studied. Whilst studies like these show a benefit for res-
ponders they do not address the question as to whether or
not the therapy under question is improving survival for the
group as a whole.
The present study suggests that there is a positive cor-
relation between improved response and improved survival
though it is impossible to rule out the existence of publica-
tion bias. The relationship between relative response rates
and relative median survivals suggests that for differences in
response rates such as are commonly seen in trials of
chemotherapy regimens only modest benefits in median
survival would be expected. For example, a trial comparing
two arms, one of which has a response rate of 40% and the
other a response rate of 20%, would be expected to show a
30 % increase in median survival in the arm with the higher
response rate.
If, for example, the arm with the 20% response rate had a
median survival of 18 months one would expect the other
arm to have a median survival of 23 months.
There are two possible criticisms of this study. Firstly, the
median survivals only represent the survival experience up to
the median survival time, so inferences cannot be drawn
about survival beyond this time. Secondly, patients have to
live long enough to experience a response, if one group has
inferior survival due to chance it may also show a poorer
response rate because some patients did not survive long
enough to demonstrate a response. This effect would tend to
enhance the relationship between response rates and survival.
The correlation between LOR and the number of patients
in a comparison suggests the existence of publication bias,
small trials may be more likely to be published if there is a
large difference in response rates. However, there are other618 R.P. A'HERN et al.
factors which may cause or contribute to such a relationship.
Firstly, such an association is a mathematical necessity.
Suppose, for example, there were a number of comparisons
looking at the same treatments which have given 'true' LOR.
In small comparisons there will be a larger distribution of
values estimating this value (due to a larger sampling error)
than in large trials, if any comparisons gave an estimate
falling below zero the odds ratio will then be reversed (since
the group with the higher response rate has now changed).
In large trials there will tend to be fewer high estimates of
the LOR and also fewer falling below zero. Hence the
average LOR will tend to be higher in the smaller trials. The
second factor which may contribute to the relationship
between LOR and the number of patients in a comparison is
that trials which show a large difference in response rates
may have fewer patients because they were terminated
sooner having satisfied stopping criteria or exhausted en-
thusiasm for participation.
An important question not addressed by this study is the
effectiveness of particular regimens in producing response
and increasing survival, only an 'average' relationship
between response and survival has been calculated. Thus it is
possible that some regimens show no relationship, or a
negative relationship and that others show a strong associa-
tion. The inadequate size of many trials means that it may
not be possible to assess the effect of many regimens on
survival. Overviews employing individual patient data would
maximise the use of the available information and may
therefore be a worthwhile undertaking for those comparisons
with large enough numbers of patients.
Appendix I
Use of the log odds ratio to measure the association between
treatment and response.
The log odds ratio was chosen as a measure of the
association between treatment and response both because it
is suggested by the logistic model and it remains valid under
other models, see for example Cox, 1970.
The response rate in the arm of a trial depends on both
the prognosis of the patients and the regimen they received.
In terms of a logistic model the response rate RA can be
written
I
RA= 1 +e(cX+a)
where x is a covariate measuring prognosis, the parameter c
measures the relationship between response rate and prog-
nosis and e=2.718 is the base of natural logarithms. The
parameter a measures the dependence of the response rate
on regimen A. Similarly, for regimen B, the response rate
can be written
RB= (Xb
The odds of response given A is then
RA =ecx+a (1)
1-RA
and similarly for regimen B the odds of response are
ecx+b (2)
Dividing (1) by (2) and taking logs then gives the log odds
ratio a-b. The effect of the regimens is thus reflected only
in the magnitude of a-b and is independent of prognosis. It
would therefore be anticipated that comparisons of the same
regimens, but from different trials, would have the same log
odds ratio despite any differences in patient prognosis
between trials. This statistic is thus suitable for comparisons
across trials. The estimate of the log odds ratio recom-
mended by Gart (1966) has been used here, this estimate was
found to be preferable to other estimates by this author and
has the advantage of being defined if the number of
responders or non-responders in either of the two groups is
zero. The high values of LOR seen in this study arise from
such comparisons, or from comparisons with a low (<5%)
response rate.
Appendix II
The regression equation implies that for values of LOR in
excess of 3.24 there would be poorer survival in the arm with
the higher response rate. However, this conclusion should be
regarded with caution in view of the sensitivity of fitted
regression lines to outliers. Comparisons with high log odds
ratios had a zero or low response rate in one arm. Though
the model which gives the best fit to all the comparisons
includes a quadratic term this term is no longer statistically
significant if the comparisons with a zero response rate in
one arm are excluded. It is worth noting in this context that
the fitted values for the two models fitting a straight line and
a curved line to all the comparisons are similar over the
range to zero to 1.5 (90% or values of LOR fall within this
range). The fitted values over the range 0 to 2.5 are shown
in Table II.
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